Literature DB >> 22802228

Why do we need a selective angiotensin II type 2 receptor agonist?

Daniel Henrion.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22802228     DOI： 10.1161/HYPERTENSIONAHA.112.197046

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  7 in total

Review 1.  Update on the angiotensin AT(2) receptor.

Authors:  Claudia A McCarthy; Robert E Widdop; Kate M Denton; Emma S Jones
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

Review 2.  Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?

Authors:  Ali Nehme; Kazem Zibara
Journal:  Hypertens Res       Date:  2017-07-06       Impact factor: 3.872

3.  Regulation of angiotensin II type 2 receptor gene expression in the adrenal medulla by acute and repeated immobilization stress.

Authors:  Regina Nostramo; Andrej Tillinger; Juan M Saavedra; Ashok Kumar; Varunkumar Pandey; Lidia Serova; Richard Kvetnansky; Esther L Sabban
Journal:  J Endocrinol       Date:  2012-08-21       Impact factor: 4.286

4.  The Role of Angiotensin II in Glomerular Volume Dynamics and Podocyte Calcium Handling.

Authors:  Daria V Ilatovskaya; Oleg Palygin; Vladislav Levchenko; Bradley T Endres; Alexander Staruschenko
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

5.  The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.

Authors:  Peter Verbrugghe; Jelle Verhoeven; Marnick Clijsters; Dominique Vervoort; Jarne Schepens; Bart Meuris; Paul Herijgers
Journal:  J Cardiovasc Pharmacol       Date:  2018-04       Impact factor: 3.105

Review 6.  Angiotensin II during Experimentally Simulated Central Hypovolemia.

Authors:  Theo Walther Jensen; Niels Vidiendal Olsen
Journal:  Front Cardiovasc Med       Date:  2016-03-03

7.  TWIRLS, a knowledge-mining technology, suggests a possible mechanism for the pathological changes in the human host after coronavirus infection via ACE2.

Authors:  Xiaoyang Ji; Wenting Tan; Chunming Zhang; Yubo Zhai; Yiching Hsueh; Zhonghai Zhang; Chunli Zhang; Yanqiu Lu; Bo Duan; Guangming Tan; Renhua Na; Guohong Deng; Gang Niu
Journal:  Drug Dev Res       Date:  2020-07-13       Impact factor: 5.004
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.